Investigational VEGF antagonists for psoriasis

Expert Opinion on Investigational Drugs

Volumn 21, Issue 1, 2012, Pages 33-43

  Crawshaw, A A ^a   Griffiths, C E M ^a   Young, H S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiogenesis; Psoriasis; Treatment; Vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; BEVACIZUMAB; IMMUNOGLOBULIN G1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NVP BAW 2881; PLACENTAL GROWTH FACTOR; PROTEIN C JUN; RETINOIC ACID; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR JUNB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ALOPECIA; ANGIOGENESIS; APOPTOSIS; ARTICLE; BINDING AFFINITY; BLEEDING; CHRONIC DISEASE; COLORECTAL CARCINOMA; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HLA SYSTEM; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KNOCKOUT MOUSE; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NONHUMAN; PHOTOCHEMOTHERAPY; PROTEIN EXPRESSION; PROTEINURIA; PSORIASIS; PUVA; REMISSION; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INFLAMMATION; STOMATITIS; TASTE DISORDER; TRANSGENIC MOUSE; ULTRAVIOLET B RADIATION; UPREGULATION; UROGENITAL TRACT CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PSORIASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REMISSION INDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84555190295     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.636351     Document Type: Article

References (83)

1. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7 (Pubitemid 29418506)
3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73
4. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803 (Pubitemid 37328914)
5. Brenchley PEC. Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. Clin Exp Immunol 2000;121:426-9
6. Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001;1:703-18 (Pubitemid 33769081)
7. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6 (Pubitemid 24256627)
8. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611 (Pubitemid 39099316)
9. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007;16:83-107 (Pubitemid 44964169)
10. Canavese M, Altruda F, Ruzicka T, et al. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-a possible target for novel therapies? J Dermatol Sci 2010;58:171-6
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76 (Pubitemid 36749215)
12. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-45
13. Bhushan M, McLaughlin B, Weiss JB, et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141:1054-60 (Pubitemid 30046195)
14. Young HS, Summers AM, Bhushan M, et al. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004;122:209-15 (Pubitemid 38114658)
15. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006;126:453-9 (Pubitemid 43323183)
16. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 2004;1:39-43 (Pubitemid 40812647)
17. Winder T, Lenz HJ. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology 2010;138:2163-76
18. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72
19. Chiang A, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2011;22:199-204
20. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32
21. Nestle FO, Kaplan DH, Barker JNWN. Psoriasis. N Engl J Med 2009;361:496-509
22. Folkman J. Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol 1972;59:40-3
23. Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-8 (Pubitemid 36759650)
24. Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008;173:265-77 (Pubitemid 351947973)
25. Schonthaler HB, Huggenberger R, Wculek SK, et al. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proceedings of the National Academy of Sciences of the United States of America; 2009. p. 21264-9
26. Jung K, Lee D, Lim HS, et al. Double Anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-{alpha} in retinopathy and psoriasis. J Biol Chem 2011;286:14410-18
27. Kunstfeld R, Hirakawa S, Hong YK, et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004;104:1048-57 (Pubitemid 39038025)
28. Akman A, Yilmaz E, Mutlu H, et al. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 2009;34:e202-4
29. Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 2007;149:103-6 (Pubitemid 46275576)
30. Fournier C, Tisman G. Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J 2010;16:17
31. Narayanan S, Callis-Duffin K, Batten J, et al. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci 2010;339:580-1
32. Flisiak I, Zaniewski P, Rogalska-Taranta M, et al. Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations. J Eur Acad Dermatol Venereol 2011. [Epub ahead of print]
33. Akman A, Dicle O, Yilmaz F, et al. Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB. Photodermatol Photoimmunol Photomed 2008;24:123-7 (Pubitemid 351682226)
34. Hernandez GL, Volpert OV, Iniguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001;193:607-20 (Pubitemid 32539557)
35. Meissner M, Doll M, Hrgovic I, et al. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol 2011;131:1356-64
36. Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006;54:1003-12
37. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004;6:R326-34
38. Creamer D, Allen M, Jaggar R, et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002;138:791-6 (Pubitemid 34625524)
39. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998;111:1-6 (Pubitemid 28309201)
40. Andressen C, Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt 1982;33:214-17 (Pubitemid 12140941)
41. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974;109:207-11
42. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535-46 (Pubitemid 350087600)
43. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64:37-9
44. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42:985-90
45. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6:813-20 (Pubitemid 27199077)
46. Brogan IJ, Khan N, Isaac K, et al. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999;60:1245-9 (Pubitemid 30017507)
47. Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000;12:1232-5 (Pubitemid 30611801)
48. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94 (Pubitemid 36935331)
49. Diaz F, Bourguignon LY. Selective down-regulation of IP(3)receptor subtypes by caspases and calpain during TNF alpha-induced apoptosis of human T-lymphoma cells. Cell Calcium 2000;27:315-28
50. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83 (Pubitemid 32448325)
51. Young HS, Janes L, Plant D, et al. Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) in inflammatory skin disease. 4th International Congress The Royal College of Physicians; London, UK; 2005. p. 154
52. Fisher LB, Maibach HI. The effect of anthralin and its derivatives on epidermal cell kinetics. J Invest Dermatol 1975;64:338-41
53. Andrys C, Borska L, Pohl D, et al. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res 2007;298:479-83 (Pubitemid 46295060)
54. Deng H, Yan CL, Hu Y, et al. Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro. Photodermatol Photoimmunol Photomed 2004;20:191-9 (Pubitemid 39077015)
55. Yano K, Kadoya K, Kajiya K, et al. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 2005;152:115-21
56. Arbiser JL. Fumarate esters as angiogenesis inhibitors: key to action in psoriasis? J Invest Dermatol 2011;131:1189-91
57. Garcia-Caballero M, Mari-Beffa M, Medina MA, et al. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect? J Invest Dermatol 2011;131:1347-55
58. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998;273:22128-35 (Pubitemid 28405397)
59. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12:356-61 (Pubitemid 46556802)
60. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-18 (Pubitemid 47036205)
61. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131-8
62. Summers J, Cohen MH, Keegan P, et al. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010;15:104-11
63. Geiger-Gritsch S, Stollenwerk B, Miksad R, et al. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010;15:1179-91
64. Lien S, Lowman HB. Therapeutic anti-VEGF antibodies. Handb Exp Pharmacol 2008;181:131-50
65. O'Connor JP, Carano RA, Clamp AR, et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15:6674-82
66. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75 (Pubitemid 41613493)
67. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
68. Leighl NB, Raez LE, Besse B, et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum-and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010;5:1054-9
69. FDA Panel Recommends Approval of Aflibercept for Wet AMD. 20/06/2011 Available from: http://www.medscape. com/viewarticle/744920 [Last accessed 23 July 2011]
70. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2011. [Epub ahead of print]
71. Twardowski P, Stadler WM, Frankel P, et al. Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California cancer Consortium trial. Urology 2010;76:923-6
72. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol 2011;29:2689-95
73. Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998;17:155-61 (Pubitemid 28391949)
74. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37 (Pubitemid 36109749)
75. Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 2011;71:1179-91
76. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-13 (Pubitemid 46143508)
77. Menter A, Griffiths CEM. Current and future management of psoriasis. Lancet 2007;370:272-84 (Pubitemid 47071926)
78. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-53 (Pubitemid 47348120)
79. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612 (Pubitemid 43815979)
80. Hutson TE, Bellmunt J, Porta C, et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III target. Eur J Cancer 2010;46:2432-40
81. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008 134:379 (Pubitemid 351173079)
82. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400 (Pubitemid 38618122)
83. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006;281:6625-31 (Pubitemid 43847597)